Integer (NYSE:ITGR) Given New $110.00 Price Target at Truist Financial

Integer (NYSE:ITGR) had its price objective boosted by Truist Financial from $97.00 to $110.00 in a research note published on Thursday morning, Marketbeat Ratings reports. They currently have a buy rating on the medical equipment provider’s stock.

Other equities research analysts have also issued research reports about the company. Zacks Research lowered Integer from a “hold” rating to a “strong sell” rating in a research report on Monday, May 11th. Piper Sandler reaffirmed an “overweight” rating and issued a $97.00 price target (up from $87.00) on shares of Integer in a report on Friday, May 1st. Citigroup increased their price target on shares of Integer from $92.00 to $96.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Integer in a report on Thursday, June 18th. Four equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $101.14.

Integer Stock Performance

NYSE:ITGR opened at $99.14 on Thursday. The firm has a market capitalization of $3.37 billion, a PE ratio of 24.72, a price-to-earnings-growth ratio of 2.28 and a beta of 0.64. The business’s fifty day moving average price is $91.38 and its 200 day moving average price is $87.44. The company has a debt-to-equity ratio of 0.77, a current ratio of 3.75 and a quick ratio of 2.38. Integer has a 12 month low of $62.00 and a 12 month high of $117.58.

Integer (NYSE:ITGR) last posted its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported $1.20 earnings per share for the quarter, missing analysts’ consensus estimates of $1.21 by ($0.01). The business had revenue of $439.58 million during the quarter, compared to analyst estimates of $426.48 million. Integer had a net margin of 7.64% and a return on equity of 12.83%. The firm’s quarterly revenue was up .5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.31 earnings per share. Integer has set its FY 2026 guidance at 5.830-6.400 EPS. On average, sell-side analysts anticipate that Integer will post 6.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ITGR. Salomon & Ludwin LLC lifted its stake in Integer by 46.8% in the fourth quarter. Salomon & Ludwin LLC now owns 370 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 118 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Integer by 48.1% during the first quarter. EverSource Wealth Advisors LLC now owns 360 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 117 shares during the last quarter. TD Private Client Wealth LLC increased its holdings in shares of Integer by 1,037.5% in the 4th quarter. TD Private Client Wealth LLC now owns 455 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 415 shares during the period. Parkside Financial Bank & Trust increased its holdings in shares of Integer by 135.5% in the 4th quarter. Parkside Financial Bank & Trust now owns 464 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 267 shares during the period. Finally, Arax Advisory Partners raised its position in Integer by 2,489.5% in the 4th quarter. Arax Advisory Partners now owns 492 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 473 shares during the last quarter. Institutional investors and hedge funds own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.